查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2004811

植入式心臟节律管理设备市场：按设备类型、技术、组件、年龄层和最终用户划分－2026-2032年全球市场预测

Implantable Cardiac Rhythm Management Devices Market by Device Type, Technology, Component, Age Group, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，植入式心臟节律管理设备市场价值将达到 168 亿美元，到 2026 年将成长至 185.7 亿美元，到 2032 年将达到 327.6 亿美元，年复合成长率为 10.01%。

主要市场统计数据
基准年 2025 168亿美元
预计年份：2026年 185.7亿美元
预测年份 2032 327.6亿美元
复合年增长率 (%) 10.01%

简要概述了影响植入式心臟节律管理的各种技术、临床实践和护理服务模式之间不断演变的相互作用。

植入式心臟节律管理领域融合了先进的电生理技术、设备小型化和不断发展的临床路径。近年来，设备演算法的进步、电池寿命的延长以及导线设计的迭代改进，共同提升了心臟起搏器、植入式心臟整流去颤器（ICD）和心臟再同步治疗（CRT）系统的安全性和治疗精准度。这些技术进步已建立起成熟的依证，为急性期手术通讯协定和长期病患管理提供了指导。

新型设备智慧、远端监控的普及以及先进的导线创新如何重塑临床实践和商业策略。

在植入式心臟节律管理领域，正在发生多项变革性变化，这些变化正在重新定义临床预期和商业性重点。设备中嵌入的智慧演算法提高了识别心律不整和提供个人化治疗的能力，从而减少了不必要的治疗并延长了设备的使用寿命。同时，追踪方式从面对面咨询转向远端监测平台，正在改变我们与患者的互动方式，并使我们能够更早发现与设备或疾病相关的变化。

评估近期美国关税调整对2025年供应链韧性、筹资策略和医疗保健服务动态的累积影响。

2025年，美国累积关税调整进一步加剧了本已错综复杂的植入式心臟器械全球供应链的复杂性。部分零件和成品进口关税的提高，推高了依赖海外原料和组件的供应商的采购成本。因此，製造商重新评估了采购地点，尽可能优先考虑在地采购，并加快供应商多元化，以缓解利润压力，维持医疗系统的价格竞争力。

基于细分市场的观点揭示了影响策略和创新的因素，其中设备类型、技术选择、组件、医疗保健服务环境和患者年龄的差异相互交织。

有效的細項分析揭示了不同设备类型、技术、组件、终端用户和患者年龄组别中微妙的需求驱动因素和扩散曲线。基于装置类型，心臟再同步治疗设备、植入式心臟整流去颤器和心律调节器之间的临床和商业性差异仍然是产品定位的核心。在心臟再同步治疗设备中，具有去心房颤动功能的系统和仅具备起搏功能的再同步平台之间的差异会影响植入的复杂性、追踪频率和多学科护理计划。基于技术，双心室、双腔和单腔系统之间的治疗和手术权衡仍然是指南原则，这些标准反映了患者特定的传导异常和心臟衰竭表型。

北美、欧洲、中东和非洲以及亚太地区的区域趋势和市场准入要求将决定引入、兑换和伙伴关係策略。

区域趋势对植入式心律不整治疗领域的临床导入模式、监管应对措施和商业化策略有显着影响。在美洲，医疗服务体系和报销框架支持循证器械疗法的快速推广，而公立和私立保险公司之间的差异则影响采购週期和合约谈判。在欧洲、中东和非洲，不同的管理体制和医疗基础设施要求个人化的市场准入策略，临床证据与当地关键意见领袖（KOL）之间的合作对于成功推广至关重要，尤其是在资源有限的环境中。

竞争差异化、策略伙伴关係和整合服务模式如何推动整个医疗设备市场的产品蓝图和临床医生采用？

在植入式心臟节律管理（EMR）领域，主要企业之间的竞争与合作正在影响着创新步伐、定价趋势和临床教育工作。产业相关人员正优先考虑差异化的价值提案，这些主张结合了耐用硬体、先进的感测功能和整合式远端监测平台，以赢得临床医生的青睐。策略性倡议包括开发模组化平台以简化跨司法管辖区的监管申报流程，精简产品组合以专注于高价值槓桿，以及透过有针对性的併购来弥合技术或地理差距。

为了产生持久的影响，医疗设备製造商和供应商需要采取有针对性的策略行动，以协调创新、供应链韧性、临床培训和监管合规性。

产业领导企业应采取一系列切实可行的措施，将创新、实际应用和临床影响连结起来。首先，投资于设备智慧化和互通性，使设备不仅能够提供治疗，还能产生可用于临床的数据，从而支援长期照护路径。其次，优先考虑供应链韧性，尽可能采用多源采购、近岸外包以及透明的供应商审核，以降低贸易中断和关税波动的风险。

采用综合的、以证据为基础的调查方法，结合对临床医生的访谈、技术文件的审查、监管分析和供应链映射，以确保获得可靠的见解。

本研究采用跨学科方法，结合对关键相关人员的访谈、医疗设备技术文件的审查以及对二手文献的分析，旨在获得关于植入式心律不整管理领域的可靠且可重复的见解。主要资讯来源包括对电生理学家、心臟衰竭专家、采购经理和相关医疗保健专业人员的结构化访谈，以了解手术流程、推广应用障碍和临床疗效优先事项。这些定性资讯与器械附加檔、监管申报文件和同行评审的临床研究进行交叉比对，以检验性能声明和安全性数据。

整合临床、营运和政策因素，以确定未来设备部署、护理优化和相关人员合作的路径。

设备层面的创新、不断演进的诊疗路径以及不断变化的政策环境的融合，为整个植入式心臟节律管理生态系统中的相关人员带来了挑战和机会。感测演算法、导线耐久性和远端监测技术的进步，使得以患者为中心的诊疗模式得以实现，但这些进步必须伴随采购、临床医生培训和上市后监测等方面的营运调整。关税导致的供应链中断凸显了多元化采购和合约柔软性对于保障患者获得必要治疗的重要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：植入式心臟节律管理设备市场：依设备类型划分

  • 心臟再同步治疗装置
    • 心臟再同步治疗去心房颤动
    • 心臟再同步治疗起搏器
  • 植入式心臟整流去颤器
  • 起搏器

第九章：植入式心臟节律管理设备市场：依技术划分

  • 双心室型
  • 双腔体
  • 单人房

第十章：植入式心臟节律管理设备市场：依组件划分

  • 带领
    • 心房导线
    • 冠状窦导线
    • 心室导线
  • 脉衝发生器

第十一章：植入式心臟节律管理设备市场：依年龄组别划分

  • 成人版
  • 儿童

第十二章：植入式心臟节律管理设备市场：依最终用户划分

  • 门诊手术中心
  • 心臟病诊所
  • 医院

第十三章：植入式心臟节律管理设备市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：植入式心臟节律管理设备市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：植入式心臟节律管理设备市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国植入式心臟节律管理设备市场

第十七章：中国植入式心臟节律管理设备市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Biosense Webster
  • Biotronik SE & Co. KG
  • Boston Scientific Corporation
  • Cardiac Science Corporation
  • Cook Medical Incorporated
  • Imricor Medical Systems
  • Integer Holdings Corporation
  • LivaNova PLC
  • Medtronic plc
  • MicroPort Scientific Corporation
  • Osypka Medical GmbH
  • St. Jude Medical
Product Code: MRR-742BD517F8D1

The Implantable Cardiac Rhythm Management Devices Market was valued at USD 16.80 billion in 2025 and is projected to grow to USD 18.57 billion in 2026, with a CAGR of 10.01%, reaching USD 32.76 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 16.80 billion
Estimated Year [2026] USD 18.57 billion
Forecast Year [2032] USD 32.76 billion
CAGR (%) 10.01%

A concise orientation to the evolving interplay of technology, clinical practice, and care delivery models shaping implantable cardiac rhythm management

The implantable cardiac rhythm management domain stands at the intersection of advanced electrophysiology, device miniaturization, and evolving clinical pathways. Recent progress in device algorithms, improvements in battery longevity, and iterative lead design have collectively enhanced the safety and therapeutic precision of pacemakers, implantable cardioverter defibrillators, and cardiac resynchronization systems. These technological advancements are accompanied by a maturing evidence base that informs both acute procedural protocols and longitudinal patient management.

Clinicians face the dual challenge of integrating device-level innovation while optimizing downstream care pathways and reimbursement alignment. As hospitals and cardiac specialty clinics adopt remote monitoring and telehealth-enabled follow-up, patient engagement and data analytics are becoming core enablers of value-based care. Simultaneously, manufacturers must reconcile regulatory rigor, supply chain resilience, and clinician preference heterogeneity to ensure devices translate into measurable clinical benefit.

How emergent device intelligence, remote monitoring proliferation, and refined lead innovations are reshaping clinical practice and commercial strategy

The landscape for implantable cardiac rhythm management is undergoing several transformative shifts that are redefining clinical expectations and commercial priorities. Algorithmic intelligence embedded within devices is enhancing arrhythmia discrimination and personalized therapy delivery, which reduces inappropriate therapies and supports longer device longevity. Concurrently, the migration of follow-up from in-person visits to remote monitoring platforms is altering the modalities of patient engagement and enabling earlier detection of device- or disease-related changes.

In parallel, lead design improvements-focused on fixation mechanisms, durability, and biocompatibility-are reducing complication rates and expanding the pool of eligible patients, including those with complex anatomy. The integration of software-driven diagnostics with wearables and implantable sensors is fostering a more holistic rhythm management ecosystem, where data interoperability and cybersecurity have elevated strategic importance. Clinical pathways are adapting as electrophysiologists and multidisciplinary heart failure teams collaborate to optimize device selection and timing, emphasizing outcomes such as functional capacity and reduction of hospital readmissions.

Assessing the cumulative implications of recent United States tariff adjustments on supply chain resilience, procurement strategy, and care delivery dynamics in 2025

In 2025, cumulative tariff adjustments in the United States introduced additional complexity to an already intricate global supply chain for implantable cardiac devices. Increased import duties on certain components and finished devices raised procurement costs for suppliers who rely on internationally sourced materials and subassemblies. Consequently, manufacturers reassessed sourcing footprints, prioritized local content where feasible, and accelerated supplier diversification efforts to mitigate margin pressure and maintain competitive pricing for health systems.

These tariff-induced shifts had downstream effects on inventory strategies and capital procurement cycles at hospitals and ambulatory surgical centers. Providers reassessed device utilization protocols and procurement timelines to manage cost variability and avoid supply interruptions. At the same time, device manufacturers intensified dialogue with regulatory bodies and payers to ensure that incremental cost pressures did not undermine access to clinically indicated therapies. Overall, tariffs amplified the importance of supply chain transparency and operational agility, prompting long-term investments in nearshoring, vendor consolidation, and contract renegotiation to safeguard continuity of care.

Segment-driven perspectives revealing where device type distinctions, technology choices, components, care settings, and patient age converge to shape strategy and innovation

Meaningful segmentation analysis reveals nuanced demand drivers and adoption curves across device types, technologies, components, end users, and patient age categories. Based on device type, the clinical and commercial distinctions between cardiac resynchronization therapy devices, implantable cardioverter defibrillators, and pacemakers remain central to product positioning; within cardiac resynchronization therapy devices, differentiation between defibrillator-enabled systems and pacemaker-only resynchronization platforms has implications for implantation complexity, follow-up intensity, and multidisciplinary care planning. Based on technology, the therapeutic and procedural trade-offs among biventricular, dual chamber, and single chamber systems continue to guide selection criteria that reflect patient-specific conduction abnormalities and heart failure phenotypes.

Based on component, the architecture split between leads and pulse generators underscores where incremental innovation is most impactful; lead subtypes such as atrial leads, coronary sinus leads, and ventricular leads present distinct engineering challenges and clinical failure modes that shape R&D priorities. Based on end user, service delivery settings ranging from ambulatory surgical centers to cardiac specialty clinics and hospitals dictate workflow integration, device inventory strategies, and required clinical competencies for implantation and follow-up. Based on age group, adult and pediatric patient populations impose divergent design considerations, regulatory pathways, and long-term surveillance needs, compelling manufacturers to balance modular platform approaches with age-specific safety and ergonomics.

Regional dynamics and market entry imperatives across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine adoption, reimbursement, and partnership strategies

Regional dynamics exert a powerful influence on clinical adoption patterns, regulatory navigation, and commercialization tactics across the implantable rhythm management space. In the Americas, care delivery architectures and reimbursement frameworks support rapid uptake of evidence-based device therapies, while differences between public and private payers influence procurement cycles and contractual negotiations. In the Europe, Middle East & Africa corridor, heterogeneous regulatory regimes and varied healthcare infrastructure demand tailored market entry approaches, with clinical evidence and local KOL engagement being pivotal to adoption, particularly in constrained-resource settings.

In the Asia-Pacific region, demographic trends and expanding access to tertiary electrophysiology services are driving interest in both advanced device platforms and cost-effective alternatives; regional manufacturing ecosystems and public procurement mechanisms can create competitive opportunities for localized production and strategic partnerships. Across all regions, cross-border data governance, clinical trial diversification, and training initiatives remain essential to scaling device adoption and ensuring consistent standards of care.

How competitive differentiation, strategic partnerships, and integrated service models are steering product roadmaps and clinician adoption across the device landscape

Competitive and collaborative behaviors among leading companies influence the pace of innovation, pricing dynamics, and clinical education efforts in implantable cardiac rhythm management. Industry players prioritize differentiated value propositions that combine durable hardware, advanced sensing capabilities, and integrated remote monitoring platforms to drive clinician preference. Strategic activities include modular platform development to streamline regulatory filings across jurisdictions, portfolio rationalization to focus on high-value levers, and targeted M&A to fill technology or geographic gaps.

Partnerships with health systems and academic centers accelerate real-world evidence generation and refine indications for use, while vendor investments in training academies and implant support services underpin adoption. Supply chain partnerships and long-term procurement agreements with end users aim to stabilize device availability and align incentives around patient outcomes. Finally, increased focus on cybersecurity and post-market surveillance is reshaping product development roadmaps and aftermarket service models to support device safety and longevity.

Targeted strategic actions for device makers and providers to align innovation, supply chain resilience, clinical training, and regulatory readiness for sustained impact

Industry leaders should pursue a set of actionable steps that bridge innovation with operational execution and clinical impact. First, invest in device intelligence and interoperability to ensure devices not only deliver therapy but also generate clinically actionable data that supports longitudinal care pathways. Second, prioritize supply chain resiliency through multi-sourcing, nearshoring where feasible, and transparent supplier auditing to reduce vulnerability to trade disruptions and tariff volatility.

Third, strengthen clinician and center-level training programs to accelerate procedural proficiency and optimize patient selection, especially for advanced therapies such as resynchronization systems. Fourth, pursue region-specific commercialization strategies that reflect local reimbursement mechanisms, regulatory requirements, and provider capacity, while leveraging real-world evidence to support payer conversations. Fifth, embed cybersecurity and post-market surveillance into product lifecycles to maintain trust and regulatory compliance. Finally, consider modular platform strategies that can be adapted for adult and pediatric markets to maximize lifecycle value while meeting specialized clinical needs.

An integrated, evidence-driven methodology combining clinician interviews, technical dossier review, regulatory analysis, and supply chain mapping to ensure robust insights

This research synthesis integrates a multidisciplinary approach combining primary stakeholder interviews, device technical dossier reviews, and secondary literature analysis to produce a robust and reproducible view of the implantable rhythm management sector. Primary inputs include structured interviews with electrophysiologists, heart failure specialists, procurement leaders, and allied health professionals to capture procedural insights, adoption barriers, and clinical outcome priorities. These qualitative inputs were triangulated with device labeling, regulatory filings, and peer-reviewed clinical studies to validate performance claims and safety profiles.

Operational and commercial context was informed by supply chain mapping and public policy reviews to assess sourcing risks and tariff implications. The methodology emphasizes transparency in source attribution, rigorous cross-validation of claims, and sensitivity testing of strategic assumptions to ensure findings are resilient to varying clinical and regulatory scenarios. Where possible, longitudinal clinical registries and post-market surveillance data were examined to corroborate complication rates and device performance trends.

Synthesis of clinical, operational, and policy factors that converge to define future pathways for device adoption, care optimization, and stakeholder collaboration

The convergence of device-level innovation, shifting care pathways, and evolving policy contexts presents both challenges and opportunities for stakeholders across the implantable cardiac rhythm management ecosystem. Advancements in sensing algorithms, lead durability, and remote monitoring are enabling more patient-centric models of care, yet these advances must be matched by operational adaptations in procurement, clinician training, and post-market oversight. Tariff-induced supply chain disruptions highlight the need for diversified sourcing and contract agility to preserve access to essential therapies.

Going forward, success will depend on the ability of manufacturers and providers to translate technological capabilities into reproducible clinical outcomes, to collaborate on real-world data generation, and to adopt regionally nuanced commercialization approaches. By aligning technical innovation with pragmatic operational and clinical strategies, stakeholders can enhance patient outcomes while navigating the complex regulatory, economic, and logistical contours of rhythm management care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Implantable Cardiac Rhythm Management Devices Market, by Device Type

  • 8.1. Cardiac Resynchronization Therapy Device
    • 8.1.1. Cardiac Resynchronization Therapy Defibrillator
    • 8.1.2. Cardiac Resynchronization Therapy Pacemaker
  • 8.2. Implantable Cardioverter Defibrillator
  • 8.3. Pacemaker

9. Implantable Cardiac Rhythm Management Devices Market, by Technology

  • 9.1. Biventricular
  • 9.2. Dual Chamber
  • 9.3. Single Chamber

10. Implantable Cardiac Rhythm Management Devices Market, by Component

  • 10.1. Leads
    • 10.1.1. Atrial Leads
    • 10.1.2. Coronary Sinus Leads
    • 10.1.3. Ventricular Leads
  • 10.2. Pulse Generator

11. Implantable Cardiac Rhythm Management Devices Market, by Age Group

  • 11.1. Adult
  • 11.2. Pediatric

12. Implantable Cardiac Rhythm Management Devices Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Cardiac Specialty Clinics
  • 12.3. Hospitals

13. Implantable Cardiac Rhythm Management Devices Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Implantable Cardiac Rhythm Management Devices Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Implantable Cardiac Rhythm Management Devices Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Implantable Cardiac Rhythm Management Devices Market

17. China Implantable Cardiac Rhythm Management Devices Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Biosense Webster
  • 18.7. Biotronik SE & Co. KG
  • 18.8. Boston Scientific Corporation
  • 18.9. Cardiac Science Corporation
  • 18.10. Cook Medical Incorporated
  • 18.11. Imricor Medical Systems
  • 18.12. Integer Holdings Corporation
  • 18.13. LivaNova PLC
  • 18.14. Medtronic plc
  • 18.15. MicroPort Scientific Corporation
  • 18.16. Osypka Medical GmbH
  • 18.17. St. Jude Medical

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY COMPONENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY DEFIBRILLATOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY DEFIBRILLATOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY DEFIBRILLATOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY PACEMAKER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY PACEMAKER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY PACEMAKER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY IMPLANTABLE CARDIOVERTER DEFIBRILLATOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY IMPLANTABLE CARDIOVERTER DEFIBRILLATOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY IMPLANTABLE CARDIOVERTER DEFIBRILLATOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY PACEMAKER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY PACEMAKER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY PACEMAKER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY BIVENTRICULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY BIVENTRICULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY BIVENTRICULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY DUAL CHAMBER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY DUAL CHAMBER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY DUAL CHAMBER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY SINGLE CHAMBER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY SINGLE CHAMBER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY SINGLE CHAMBER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY LEADS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY LEADS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY LEADS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY ATRIAL LEADS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY ATRIAL LEADS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY ATRIAL LEADS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY CORONARY SINUS LEADS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY CORONARY SINUS LEADS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY CORONARY SINUS LEADS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY VENTRICULAR LEADS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY VENTRICULAR LEADS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY VENTRICULAR LEADS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY PULSE GENERATOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY PULSE GENERATOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY PULSE GENERATOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY CARDIAC SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY CARDIAC SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY CARDIAC SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. GCC IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GCC IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. GCC IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 140. GCC IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. GCC IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 142. GCC IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 143. GCC IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GCC IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. G7 IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. G7 IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. G7 IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 164. G7 IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 165. G7 IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 166. G7 IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 167. G7 IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. G7 IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. NATO IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. NATO IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. NATO IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 172. NATO IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 173. NATO IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 174. NATO IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 175. NATO IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. NATO IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA IMPLANTABLE CARDIAC RHYTHM MANAGEMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)